iShares US Healthcare (IYH) Declines 0.38% for Sep 17

September 17, 2017 - By Dolores Ford

Sep 17 is a negative day so far for iShares US Healthcare (NYSEARCA:IYH) as the ETF is active during the day after losing 0.38% to hit $173.77 per share. The exchange traded fund has 2.08B net assets and 1.23% volatility this month.

Over the course of the day 43,556 shares traded hands, as compared to an average volume of 148,100 over the last 30 days for iShares US Healthcare (NYSEARCA:IYH).

The ETF is -6.39% of its 52-Week High and 15.08% of its low, and is currently having ATR of 2.39. This year’s performance is -0.96% while this quarter’s performance is -4.87%.

The ETF’s YTD performance is 0%, the 1 year is 0% and the 3 year is 0%.

More notable recent iShares Dow Jones US Healthcare (ETF) (NYSEARCA:IYH) news were published by: which released: “Mid-Day ETF Update: ETFs, Stocks Higher as Mixed Economic Data Remains In …” on September 15, 2017, also with their article: “Mid-Day ETF Update: ETFs, Stocks Mixed to Lower As Wall Street Looks Ahead to …” published on September 14, 2017, published: “Mid-Day ETF Update: ETFs, Stocks Weaker as Geopolitical Risks Resurface …” on September 05, 2017. More interesting news about iShares Dow Jones US Healthcare (ETF) (NYSEARCA:IYH) were released by: and their article: “iShares US Healthcare ETF: Is It Worth Investing Now?” published on August 28, 2017 as well as‘s news article titled: “Mid-Day ETF Update: ETFs, Stocks Mixed as Worries Over Effects of Harvey, Irma …” with publication date: September 08, 2017.

iShares U.S. Healthcare ETF , formerly iShares Dow Jones U.S. The ETF has market cap of $2.08 billion. Healthcare Sector Index Fund (the Fund) is a non-diversified exchange-traded fund. It has a 5.44 P/E ratio. The Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Dow Jones U.S.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.